<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717741</url>
  </required_header>
  <id_info>
    <org_study_id>NanjingYoko</org_study_id>
    <nct_id>NCT02717741</nct_id>
  </id_info>
  <brief_title>A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor</brief_title>
  <official_title>A Phase I Study to Determine the Safety and Pharmacokinetic Study of Tafetinib in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Yoko Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Yoko Biomedical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tafetinib is an oral multitargeted tyrosine kinase inhibitor that inhibits Vascular
      Endothelial Growth Factor Receptor (VEGFR).

      This phase I trial was conducted to evaluate the pharmacokinetics (PK), safety, and
      preliminary efficacy of tafetinib in Chinese patients with advance solid tumor. The study are
      conducting in Cancer Hospital Chinese Academy of Medical Sciences.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>3 weeks</time_frame>
    <description>Dose-limiting toxicity was defined as any one of the following (NCI-CTCAE Version 4.0): (a) hypertension: uncontrollable grade 3 hypertensive or grade 4. (b) reduced LVEF: 2 degrees or above. (c) neutropenia : 3 degrees or above. (d) thrombopenia: 3 degrees or above. (e) Other Non-hematologic toxicity (not including alopecia, nausea or vomiting): 3 degrees or above.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>tafetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tafetinib administered daily for 2 weeks, followed by a 1-week off period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tafetinib</intervention_name>
    <arm_group_label>tafetinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with histologically confirmed advanced solid malignancies.

          -  ECOG score 0-1.

          -  18-65 years old.

          -  Withdrawal other chemotherapy drugs more than 30 days. No nitrosoureas or mitomycin C
             within the previous 6 weeks.

          -  Function of organs must meet the following requirements:

          -  Neutrophil count ≥1500/ul;

          -  AST and ALT≤1.5 times the upper limit of normal (ULN);

          -  Total serum bilirubin≤1.5 times ULN;

          -  Hemoglobin≥90g/L;

          -  Platelet≥100000/ul;

          -  The creatinine in the normal range or creatinine clearance rate ≥60ml/min;

          -  Left ventricular ejection fraction (LVEF) ≥50%;

          -  Females of childbearing age are required to be practicing effective contraceptive
             measures and to have a negative serum or urine pregnancy test before study.

          -  Written informed consent is obtained.

        Exclusion Criteria:

          -  included a history of or current brain metastases, clinically significant
             cardiovascular disease or uncontrolled hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhou s Yu, dr.</last_name>
    <phone>86-10-87788293</phone>
    <email>typhoonwho@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tang Le, dr.</last_name>
    <phone>86-10-87788293</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhou s Yu, Dr.</last_name>
      <phone>86-10-87788293</phone>
      <email>typhoonwho@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

